These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 23221770)

  • 1. Clinical aspects of visceral leishmaniasis in HIV infection.
    Jarvis JN; Lockwood DN
    Curr Opin Infect Dis; 2013 Feb; 26(1):1-9. PubMed ID: 23221770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
    Ali A
    Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of leishmaniasis in HIV-positive patients.
    Laguna F
    Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():135-42. PubMed ID: 14678640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection].
    Delgado Fernández M; García Ordoñez MA; Martos Pérez F; Reguera Iglesias JM; Jiménez Oñate F; Colmenero Castillo JD
    An Med Interna; 1997 Oct; 14(10):506-10. PubMed ID: 9424140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Visceral leishmaniasis in patient with HIV infection].
    Olea P; Pinilla J
    Rev Chilena Infectol; 2013 Apr; 30(2):216-20. PubMed ID: 23677161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
    Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
    Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leishmaniasis: an update of current pharmacotherapy.
    Sundar S; Chakravarty J
    Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure--a case report and brief review of the literature.
    Rybniker J; Goede V; Mertens J; Ortmann M; Kulas W; Kochanek M; Benzing T; Arribas JR; Fätkenheuer G
    Int J Infect Dis; 2010 Jun; 14(6):e522-5. PubMed ID: 19726213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of visceral leishmaniasis: safety and efficacy.
    Jha RK; Sah AK; Shah DK; Sah P
    JNMA J Nepal Med Assoc; 2013; 52(192):645-51. PubMed ID: 25327244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous leishmaniasis associated with visceral leishmaniasis in a case of acquired immunodeficiency syndrome (AIDS).
    Pourahmad M; Hooshmand F; Rahiminejad M
    Int J Dermatol; 2009 Jan; 48(1):59-61. PubMed ID: 19126052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal amphotericin B and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS.
    Mastroianni A
    Infez Med; 2004 Sep; 12(3):197-204. PubMed ID: 15711134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
    Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
    Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
    Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
    Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Visceral leishmaniasis: clinical sensitivity and resistance to various therapeutic agents].
    Janvier F; Morillon M; Olliaro P
    Med Trop (Mars); 2008 Feb; 68(1):89-101. PubMed ID: 18478781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intestinal parasitic infections and leishmaniasis in patients with HIV infection].
    Moreno-Camacho A; López-Vélez R; Muñoz Sanz A; Labarga-Echevarría P
    Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():52-60. PubMed ID: 9859620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil.
    Daher EF; Fonseca PP; Gerhard ES; Leitão TM; Silva Júnior GB
    J Parasitol; 2009 Jun; 95(3):652-5. PubMed ID: 19642802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Visceral leishmaniasis and HIV infection in the HAART era].
    Marques N; Cabral S; Sá R; Coelho F; Oliveira J; Saraiva da Cunha JG; Meliço Silvestre A
    Acta Med Port; 2007; 20(4):291-8. PubMed ID: 18198072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple relapses of visceral leishmaniasis in a patient with HIV in India: a treatment challenge.
    Patole S; Burza S; Varghese GM
    Int J Infect Dis; 2014 Aug; 25():204-6. PubMed ID: 24927662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visceral Leishmaniasis: Recent Advances in Diagnostics and Treatment Regimens.
    van Griensven J; Diro E
    Infect Dis Clin North Am; 2019 Mar; 33(1):79-99. PubMed ID: 30712769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.